Physician profile
Eric H Jensen
NPI 1770526857
$221,327.05
in general payments reported to CMS, 2019-2025
8 companies · $46K in 2025
The $46K reported for 2025 was more than what 99% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,721 · 2020: $26K · 2021: $33K · 2022: $8,710 · 2023: $55K · 2024: $45K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $126K · Travel and Lodging: $18K · Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $125,860.00 |
| Travel and Lodging | $17,937.96 |
| Food and Beverage | $2,046.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $185,285.35 | 2019-2025 | Certus 140, Neuwave |
| Ethicon INC. | $15,660.00 | 2025 | Certus 140 |
| Ethicon US, LLC | $12,995.42 | 2021-2025 | Certus 140, Neuwave, Vistaseal |
| Ethicon Endo-Surgery INC. | $6,494.62 | 2023 | Neuflex, Certus 140 |
| Stryker Corporation | $368.63 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $300.00 | 2022 | |
| Alcresta Therapeutics, INC. | $122.73 | 2023 | Relizorb |
| Histosonics, INC. | $100.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.